Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celgosivir in chronic hepatitis C genotype 1
NCT00292084Phase 2Completed
- Sponsor
- BioWest Therapeutics
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of celgosivir in hepatitis C virus infection (2 arms), sponsored by BioWest Therapeutics. Primary endpoints: Safety analysis at 36 weeks and HCV viral load reduction from baseline at 36 weeks. Started Feb 2006; status: completed.
02
Drugs
celgosivir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00292084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292084.